HDAC2 and neoplasm: We first as proof of concept evaluated expression of JAK/HDACi targets (pJAK2, pSTAT3Y705, and HDAC2/6) and regorafenib targets (PDGFRβ, pEGFR, and pERK1/2) by western blots in tissue lysates of CRCs (T) and their corresponding normal/uninvolved tissues (N), wherein increased expression was observed in tumor tissue compared to their adjacent normal (Fig. 1A-B), indicating that targeting CRC with this combination could be promising.